<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002687</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064412</org_study_id>
    <secondary_id>UW-24218-A/E</secondary_id>
    <secondary_id>NCI-V95-0758</secondary_id>
    <nct_id>NCT00002687</nct_id>
  </id_info>
  <brief_title>Interleukin-2 in Treating Patients With Mycosis Fungoides</brief_title>
  <official_title>Phase 1 Trial of Subcutaneous [SC]; Outpatient Interleukin-2 for Patients With Advanced Mycosis Fungoides [Stage IIb, III, IV]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients who&#xD;
      have mycosis fungoides.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and toxicity of interleukin-2 in patients with&#xD;
           stage IIB-IV mycosis fungoides.&#xD;
&#xD;
        -  Determine the response rate of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the immunologic response to this regimen in peripheral blood leukocytes and&#xD;
           serum of these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive interleukin-2 (IL-2) subcutaneously on days 1-5 during weeks 1-3 and on days&#xD;
      1-3 and 5 during week 4. Treatment repeats every 4 weeks for 4 courses.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of IL-2 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose at which 3 of 6 patients experience&#xD;
      dose-limiting toxicity. Six additional patients receive IL-2 at 1 dose level preceding the&#xD;
      MTD.&#xD;
&#xD;
      Patients are followed at least 3 times during year 1 and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1995</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Clinically and histologically proven diagnosis of 1 of the following:&#xD;
&#xD;
               -  Mycosis fungoides (MF) meeting 1 of the following conditions:&#xD;
&#xD;
                    -  Stage IIB disease that has failed psoralen ultraviolet A (PUVA) light&#xD;
                       therapy and topical chemotherapy (mechlorethamine and/or carmustine)&#xD;
&#xD;
                    -  Stage III disease with generalized erythroderma&#xD;
&#xD;
                    -  Stage IV disease with biopsy proven nodal or visceral involvement&#xD;
&#xD;
               -  Sezary syndrome&#xD;
&#xD;
                    -  Stage III MF with a minimum of 20% Sezary cells (based on total WBC)&#xD;
&#xD;
          -  No clinically significant ascites or pleural effusion&#xD;
&#xD;
               -  Clinically significant pleural effusion defined as shortness of breath with&#xD;
                  oxygen saturation less than 90%&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 16 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 11.5 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.5 times normal&#xD;
&#xD;
          -  SGOT less than 2.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No nephrotic syndrome&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of myocardial infarction or congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No clinically manifest hypotension&#xD;
&#xD;
          -  No severe hypertension&#xD;
&#xD;
          -  No arrhythmia on electrocardiogram&#xD;
&#xD;
          -  No edema&#xD;
&#xD;
          -  No contraindication to pressor agents&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No dyspnea at rest or severe exertional dyspnea&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No significant CNS dysfunction, including any of the following:&#xD;
&#xD;
               -  Seizure disorder&#xD;
&#xD;
               -  Active cerebrovascular disease&#xD;
&#xD;
               -  Dementia or delirium&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No autoimmune disease, including psoriasis&#xD;
&#xD;
          -  No uncontrolled peptic ulcer disease&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No history of adverse reaction to interleukin-2&#xD;
&#xD;
          -  HIV and HTLV-I negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior systemic or topical chemotherapy (6 weeks since prior&#xD;
             mitomycin or nitrosoureas)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 1 week since prior corticosteroids&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
          -  At least 3 weeks since other prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior immunosuppressive therapy&#xD;
&#xD;
          -  At least 2 weeks since prior phototherapy (ultraviolet B [UVB] or PUVA light therapy)&#xD;
&#xD;
          -  No concurrent phototherapy (UVB or PUVA light therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A. Thompson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seattle Cancer Care Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

